New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Prognostication and risk stratification of patients with myelodysplastic syndromes.
Prognostication and risk stratification of patients with myelodysplastic syndromes. Blood DeZern, A., Greenberg, P. L. 2023Abstract
Risk stratification and prognostication are crucial for the appropriate management of patients with myelodysplastic syndromes or myelodysplastic neoplasms (MDS), for whom expected survival can vary from a few months to more than 10 years. For the past five decades, patients with MDS have been classified into higher-risk versus lower-risk disease phenotypes using sequentially developed clinical prognostic scoring systems. Factors such as morphologic dysplasia, clinical hematologic parameters, cytogenetics, and more recently, mutational information, have been captured in prognostic scoring systems which refine risk stratification and guide therapeutic management in MDS patients. This review will describe the progressive evolution and improvement of these systems to the current Molecular International Prognostic Scoring System (IPSS-M).
View details for DOI 10.1182/blood.2023020081
View details for PubMedID 37562001